Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. EXCLUSIVE LICENSE AGREEMENT BETWEEN CHILDREN’S MEDICAL CENTER CORPORATION AND ICAGEN, INC.Exclusive License Agreement • May 24th, 2004 • Icagen Inc • Pharmaceutical preparations • Massachusetts
This Agreement is made and entered into as of the date last written below (the Effective Date), by and between Children’s Medical Center Corporation, a charitable corporation duly organized and existing under the laws of the Commonwealth of Massachusetts and having its principal office at 300 Longwood Avenue, Boston, Massachusetts, 02115, U.S.A. (hereinafter referred to as “CMCC”), and ICAgen, Inc., a business corporation organized and existing under the laws of the State of Delaware and having its principal place of business located at 4222 Emperor Boulevard, Suite 460, Durham, NC 27703 (hereinafter referred to as “Licensee”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • May 24th, 2004 • Icagen Inc • Pharmaceutical preparations • Illinois
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATIVE RESEARCH AND LICENSE AGREEMENT BETWEEN ICAGEN INC. YAMANOUCHI PHARMACEUTICAL CO., LTD. DATED AS OF MARCH 21, 2000Collaborative Research and License Agreement • May 24th, 2004 • Icagen Inc • Pharmaceutical preparations • North Carolina
THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) dated as of March 21, 2000 (the “Effective Date”) is entered into by and between ICAgen Inc., a corporation duly organized and existing under the laws of the State of Delaware and having offices at 4222 Emperor Boulevard, Suite 460, Durham, North Carolina 27703 (“ICAgen”), and Yamanouchi Pharmaceutical Co., Ltd., a corporation duly organized and existing under the laws of Japan and having offices at 3-11 NihonbashiHoncho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (“YAMANOUCHI”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 24th, 2004 • Icagen Inc • Pharmaceutical preparations • Delaware
This Registration Rights Agreement (the “Agreement”) dated as of April 26, 2004 is entered into by and between Icagen, Inc., a Delaware corporation (the “Company”), and Abbott Laboratories, an Illinois corporation (“Abbott”).
FIRST AMENDMENT TO WARRANTS TO PURCHASE SHARES OF PREFERRED STOCK OF ICAGEN, INC.Warrant Amendment • May 24th, 2004 • Icagen Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT TO WARRANTS TO PURCHASE SHARES OF PREFERRED STOCK OF ICAGEN, INC. (the “First Amendment”) is entered into as of May 14, 2004, by and between Icagen, Inc., a Delaware corporation (the “Company”), and Dominion Fund III, a California limited partnership (the “Holder”) and, for the purposes of Section 6 herein, Dominion Ventures, Inc.
MASTER SERVICES AGREEMENTMaster Services Agreement • May 24th, 2004 • Icagen Inc • Pharmaceutical preparations • North Carolina
This Master Services Agreement (“Agreement”) is made between ICAgen, Inc. which has a place of business at 4222 Emperor Blvd. Suite 460, Durham, NC 27703 (hereinafter “ICAgen”), and Quintiles Inc., a North Carolina corporation having its principal place of business at 1007 Slater Road, Durham, North Carolina USA 27709 (hereinafter “Quintiles”). When signed by both parties, this Agreement will set forth the terms and conditions under which Quintiles agrees to provide certain services to ICAgen as set forth herein.
